Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus

Friedberg, Samuel J.; Lam, Y. W. Francis; Blum, J. J.; Gregerman, Robert I.

doi:10.1016/j.metabol.2005.12.004

Cited by 17 publications

(6 citation statements)

References 45 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…People with insulin-resistant Type 2 diabetes receiving basal insulin and oral anti-diabetes drug therapy often require treatment intensification with bolus insulin to improve glycaemic control [4]. However, PPG control frequently remains suboptimal, even in people receiving a high bolus insulin dose [5,6]. Further, conventional rapid-acting insulin analogues do not seem to offer a therapeutic advantage over regular human insulin in these people; this is concerning and highlights the need for more efficacious bolus insulins in this population.…”

Section: Introductionmentioning

confidence: 99%

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

et al. 2018

View full text Add to dashboard Cite

Aim This post hoc analysis explored whether mealtime fast‐acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin. Methods A post hoc, post‐randomization, subgroup analysis of a 26‐week, randomized, double‐blind, treat‐to‐target trial (onset 2) that compared mealtime fast‐acting insulin aspart vs. mealtime insulin aspart, both in a basal–bolus regimen, in people with Type 2 diabetes uncontrolled on basal insulin therapy and metformin. At the end of trial, the impact of fast‐acting insulin aspart and insulin aspart on PPG control was assessed with a standard liquid meal test and participants were grouped into three post‐randomization subgroups: meal test bolus insulin dose ≤ 10 units per dose (n = 171), > 10–20 units per dose (n = 289) and > 20 units per dose (n = 146). Results A statistically significant treatment difference in favour of fast‐acting insulin aspart vs. insulin aspart was observed for the change in PPG increment at all post‐meal time points (from 1 to 4 h) for those in the > 20 units bolus insulin subgroup. There was no difference in the magnitude of change from baseline in HbA1c level between fast‐acting insulin aspart and insulin aspart in any of the bolus insulin dose subgroups (data herein). Conclusion Fast‐acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin‐resistant Type 2 diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

et al. 2018

View full text Add to dashboard Cite

show abstract

“…NPH insulin should be reduced by one-half or one-third prior to surgery to avoid hypoglycemia. Intravenous insulin is the preferred method of insulin delivery to achieve rapid and effective glycemic control in hospitalized patients who are hyperglycemic prior to surgery [75]. It is important to identify all patients with abnormal renal function since the risk for hypoglycemia is increased in all these patients [76–78].…”

Section: Management Of Hyperglycemia In the Perioperative Periodmentioning

confidence: 99%

Glycemic Control during Coronary Artery Bypass Graft Surgery

Lazar

2012

ISRN Cardiology

View full text Add to dashboard Cite

Hyperglycemia, which occurs in the perioperative period during cardiac surgery, has been shown to be associated with increased morbidity and mortality. The management of perioperative hyperglycemia during coronary artery bypass graft surgery and all cardiac surgical procedures has been the focus of intensive study in recent years. This report will paper the pathophysiology responsible for the detrimental effects of perioperative hyperglycemia during cardiac surgery, show how continuous insulin infusions in the perioperative period have improved outcomes, and discuss the results of trials designed to determine what level of a glycemic control is necessary to achieve optimal clinical outcomes.

show abstract

“…Poor absorption of insulin is an important factor in patients with diabetes [1]. Rapid-acting insulin analogs more closely approach the physiological insulin response, compared with regular human insulin [2].…”

Section: Introductionmentioning

confidence: 99%

Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure

Shi

Zhao

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus

Cited by 17 publications

References 45 publications

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

Glycemic Control during Coronary Artery Bypass Graft Surgery

Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure

Contact Info

Product

Resources

About